Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
A phase 2 trial of Durvalumab and Gemcitabine in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Overview
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours is a phase 2 interventional study registered as NCT04999969 by AstraZeneca, with 126 participants enrolled, started 2021-12-10 and due to reach its primary completion in 2024-10-07. Interventions recorded: AZD0171, Durvalumab, Gemcitabine and Nab-paclitaxel. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Durvalumab, AstraZeneca and the tag pipeline.